Australia’s third largest company CSL Limited (CSL) posted a modest lift in full year revenue, higher costs and softer net profit. While plasma collections rose in FY22, it was done at a higher cost, flu vaccine sales improved and a near US$12b acquisition has muddied its outlook.
Originally published by CommSec
